IndraLab

Statements

Hydroxychloroquine activates prednisone. 4 / 4
| 4
reach
"Serious adverse outcomes associated with these medications include hemorrhage (apixaban), gastrointestinal bleeding, ulceration, or perforation (sulindac, prednisone), thrombotic events (sulindac), central nervous system depression (gabapentin), cardiomyopathy/conduction abnormalities, hypoglycemia, myopathy, psychosis, retinopathy (hydroxychloroquine), myopathy (hydroxychloroquine, prednisone), increased susceptibility to infections and malignancies (mycophenolate mofetil, prednisone), and adrenal suppression, psychiatric disturbances, Cushing syndrome, hyperglycemia, osteoporosis, and increased intraocular pressure (prednisone)."
37209041
reach
"Forty-five (65.2%) of the patients received oral medication for SLE treatment during pregnancy, and 44 (63.8%) were treated with prednisone and 19 (27.5%) were treated with hydroxychloroquine."
27998874
reach
"Compared to MMF new users, CYC new users had higher SLE risk adjustment indices, less frequent hydroxychloroquine use, increased hospitalizations and higher cumulative median prednisone doses."
27589220
reach
"In contrast, combined treatment with prednisone and either danazol (n = 18) or hydroxychloroquine (n = 11) resulted in 50% (7 CR, 2 PR) and 64% (4 CR, 3 PR) longterm responses, respectively, allowing prednisone to be withdrawn or the dose tapered below 0.2 mg/kg body weight and day."
11824975